Physician profile
Sean Sullivan
NPI 1407146699
$3,597.59
in general payments reported to CMS, 2019-2025
22 companies · $1,138 in 2025
The $1,138 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,460 · 2025: $1,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim International Gmbh | $2,460.00 | 2022 | |
| Medtronic, INC. | $148.88 | 2025 | Symplicity G3 |
| Novo Nordisk INC | $139.42 | 2025 | Wegovy |
| Corcept Therapeutics | $118.24 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $108.57 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $69.89 | 2025 | Zoryve |
| Janssen Biotech, INC. | $69.55 | 2025 | Tremfya |
| Amgen INC. | $67.98 | 2025 | Evenity, Otezla, Repatha |
| Xeris Pharmaceuticals, INC. | $66.46 | 2025 | Gvoke Hypopen, Recorlev |
| Pfizer INC. | $64.60 | 2025 | |
| Tandem Diabetes Care, INC. | $49.85 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Exact Sciences Corporation | $47.81 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $23.46 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $20.35 | 2025 | Shingrix |
| Sumitomo Pharma America, INC. | $18.74 | 2025 | Gemtesa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $18.68 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $18.52 | 2025 | Zenpep |
| Ani Pharmaceuticals, INC. | $18.37 | 2025 | Sovuna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.12 | 2025 | Xifaxan |
| Lilly USA, LLC | $17.92 | 2025 | Zepbound |
| Sobi, INC | $16.27 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.91 | 2025 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.